(65 days)
Not Found
No
The summary describes a bone void filler material and does not mention any software, algorithms, or AI/ML capabilities.
Yes
The device is described as an injectable filling material for bone voids, which directly treats a condition (skeletal defects) by filling them and promoting bone healing/resorption. This therapeutic action makes it a therapeutic device.
No
The device is a bone void filler, a material used to fill spaces in bones. It is not involved in identifying, analyzing, or diagnosing medical conditions.
No
The device description clearly states it is a sterile calcium sulfate powder that is mixed with a sterile setting solution, indicating it is a physical material, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to fill bone voids or gaps in the skeletal system. This is a therapeutic and structural application, not a diagnostic one.
- Device Description: The device is a bone void filler, a material used to physically fill spaces in bone. This is not a reagent, instrument, or system intended for use in the in vitro examination of specimens derived from the human body.
- Lack of Diagnostic Elements: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or providing diagnostic information about a patient's health status.
IVD devices are used to perform tests on samples taken from the body to diagnose diseases or conditions. This device is used to physically repair or augment bone structure.
N/A
Intended Use / Indications for Use
BonePlast® QS Bone Void Filler is indicated to be injected into open voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. BonePlast® QS Bone Void Filler is indicated only for bone voids or gaps that are not intrinsic to the bone structure (i.e., the extremities, spine and pelvis). The device is limited to be used in posterolateral spinal fusion procedures only.
Product codes
MQV
Device Description
BonePlast OS Bone void filler is a sterile calcium suffate powder, which is supplied dry. When mixed with sterile setting solution intra-operatively, it becomes an injectable filling material for use in non-load bearing procedures. The filler is biogradable and resorbs in approximately eight to twelve weeks, depending on the defect size, based on animal studies.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system (i.e., the extremities, spine and pelvis)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Testing: The information presented demonstrates that the BonePlast® OS Calcium Sulfate Bone Void Filler is substantially equivalent to currently marketed predicate devices. Non-clinical laboratory testing was performed to determine substantial equivalence. The results indicated that the device was functional within its intended use.
Clinical Testing: None provided as a basis for substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
JUN - 1 2007
510(K) SUMMARY
BonePlast® QS Calcium Sulfate Bone Void Filler
| Preparation Date: | May 16, 2007 |
|---|---|
| Applicant/Sponsor: | Biomet Osteobiologics |
| 100 Interpace Parkway | |
| Parsippany, NJ 07054 | |
| Establishment Registration Number: 1450662 | |
| Contact Person: | Debra Bing |
| Director of Regulatory Affairs | |
| Proprietary Name: | BonePlast® QS Calcium Sulfate Bone Void Filler |
| Common Name: | Injectable Bone Void Filler |
| Classification Name: | Filler, Bone Void, Calcium Compound (MQV/888.3045) |
Legally Marketed Devices To Which Substantial Equivalence Is Claimed:
- Calcigen™ S Bone Void Filler K013790, June 11, 2002 (Biomet Orthopedics, Inc., Warsaw, IN)
- MIIG III K024336, March 04, 2003 (Wright Medical Technology, Inc., Arlington, TN)
Device Description: BonePlast OS Bone void filler is a sterile calcium suffate powder, which is supplied dry. When mixed with sterile setting solution intra-operatively, it becomes an injectable filling material for use in non-load bearing procedures. The filler is biogradable and resorbs in approximately eight to twelve weeks, depending on the defect size, based on animal studies.
Intended Use: BonePlast® QS is indicated to be injected into open voids or gaps of the skeletal system (i.e., the extremities, spine, and pelvis). These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. BonePlast® QS Bone Void Filler is indicated only for bone voids or gaps that are not intrinsic to the stability of the bone structure (i.e., the extremities, spine, and pelvis). The device is limited to be used in posterolateral spinal fusion procedures only.
Summary of Technological The technological characteristics (materials, design sizes, and indications) are similar to or identical to that of the predicate devices to which substantial equivalence is claimed. The product is also identical in chemistry and formulation to the predicate device Calcigen™ S Bone Void Filler ( K013790).
Non-Clinical Testing: The information presented demonstrates that the BonePlast® OS Calcium Sulfate Bone Void Filler is substantially equivalent to currently marketed predicate devices. Non-clinical laboratory testing was performed to determine substantial equivalence. The results indicated that the device was functional within its intended use.
Clinical Testing: None provided as a basis for substantial equivalence.
Pg 1 of 1
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Biomet Osteobiologics % Palaniswamy Vijay, MPH, Ph.D. Manager, Applied Regulatory Technology Biomet Manufacturing Corporation P.O. Box 587 Warsaw, Indiana 46581-0587
JUN - 1 2007
Re: K070864
Trade/Device Name: BonePlast® QS Calcium Sulfate Bone Void Filler Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler Regulatory Class: Class II Product Code: MQV Dated: May 16, 2007 Received: May 17, 2007
Dear Mr. Vijay:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
2
Page 2 - Mr. Palaniswamy Vijay
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or on the Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mark A. Melheisen
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
DIGEST
INDICATIONS FOR USE
510(k) Number (if known): K070864
Device Name: BonePlast® QS Calcium Sulfate Bone Void Filler
Indications for Use:
BonePlast® QS Bone Void Filler is indicated to be injected into open voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis). These open bone voids may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. BonePlast® QS Bone Void Filler is indicated only for bone voids or gaps that are not intrinsic to the bone structure (i.e., the extremities, spine and pelvis). The device is limited to be used in posterolateral spinal fusion procedures only.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use_ NO . (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mark N. Milkerson
(Division Sign-C (Division Sign-Chi)
Division of General, Restorative,
510(k) Number
Page 1 of 1